These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 37151227)

  • 1. Cerebrospinal fluid and positron-emission tomography biomarkers for noradrenergic dysfunction in neurodegenerative diseases: a systematic review and meta-analysis.
    Lancini E; Haag L; Bartl F; Rühling M; Ashton NJ; Zetterberg H; Düzel E; Hämmerer D; Betts MJ
    Brain Commun; 2023; 5(3):fcad085. PubMed ID: 37151227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regional locus coeruleus degeneration is uncoupled from noradrenergic terminal loss in Parkinson's disease.
    Doppler CEJ; Kinnerup MB; Brune C; Farrher E; Betts M; Fedorova TD; Schaldemose JL; Knudsen K; Ismail R; Seger AD; Hansen AK; Stær K; Fink GR; Brooks DJ; Nahimi A; Borghammer P; Sommerauer M
    Brain; 2021 Oct; 144(9):2732-2744. PubMed ID: 34196700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the noradrenergic system in Parkinson's disease: an 11C-MeNER PET and neuromelanin MRI study.
    Sommerauer M; Fedorova TD; Hansen AK; Knudsen K; Otto M; Jeppesen J; Frederiksen Y; Blicher JU; Geday J; Nahimi A; Damholdt MF; Brooks DJ; Borghammer P
    Brain; 2018 Feb; 141(2):496-504. PubMed ID: 29272343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid and serum MHPG improve Alzheimer's disease versus dementia with Lewy bodies differential diagnosis.
    Janssens J; Vermeiren Y; Fransen E; Aerts T; Van Dam D; Engelborghs S; De Deyn PP
    Alzheimers Dement (Amst); 2018; 10():172-181. PubMed ID: 29552632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases.
    Betts MJ; Kirilina E; Otaduy MCG; Ivanov D; Acosta-Cabronero J; Callaghan MF; Lambert C; Cardenas-Blanco A; Pine K; Passamonti L; Loane C; Keuken MC; Trujillo P; Lüsebrink F; Mattern H; Liu KY; Priovoulos N; Fliessbach K; Dahl MJ; Maaß A; Madelung CF; Meder D; Ehrenberg AJ; Speck O; Weiskopf N; Dolan R; Inglis B; Tosun D; Morawski M; Zucca FA; Siebner HR; Mather M; Uludag K; Heinsen H; Poser BA; Howard R; Zecca L; Rowe JB; Grinberg LT; Jacobs HIL; Düzel E; Hämmerer D
    Brain; 2019 Sep; 142(9):2558-2571. PubMed ID: 31327002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoaminergic Markers Across the Cognitive Spectrum of Lewy Body Disease.
    van der Zee S; Vermeiren Y; Fransen E; Van Dam D; Aerts T; Gerritsen MJ; Spikman JM; van Laar T; De Deyn PP
    J Parkinsons Dis; 2018; 8(1):71-84. PubMed ID: 29480224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Locus Coeruleus and Noradrenergic Pharmacology in Neurodegenerative Disease.
    Matt RA; Martin RS; Evans AK; Gever JR; Vargas GA; Shamloo M; Ford AP
    Handb Exp Pharmacol; 2024; 285():555-616. PubMed ID: 37495851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noradrenergic pathways of locus coeruleus in Parkinson's and Alzheimer's pathology.
    Singh S
    Int J Neurosci; 2020 Mar; 130(3):251-261. PubMed ID: 31575316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noradrenaline in Alzheimer's Disease: A New Potential Therapeutic Target.
    Gutiérrez IL; Dello Russo C; Novellino F; Caso JR; García-Bueno B; Leza JC; Madrigal JLM
    Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Locus coeruleus integrity is related to tau burden and memory loss in autosomal-dominant Alzheimer's disease.
    Dahl MJ; Mather M; Werkle-Bergner M; Kennedy BL; Guzman S; Hurth K; Miller CA; Qiao Y; Shi Y; Chui HC; Ringman JM
    Neurobiol Aging; 2022 Apr; 112():39-54. PubMed ID: 35045380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between Cerebrospinal Fluid Core Alzheimer's Disease Biomarkers and β-Amyloid PET in Chinese Dementia Population.
    Xie Q; Ni M; Gao F; Dai LB; Lv XY; Zhang YF; Shi Q; Zhu XX; Xie JK; Shen Y; Wang SC
    ACS Chem Neurosci; 2022 May; 13(10):1558-1565. PubMed ID: 35476397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia.
    Skillbäck T; Farahmand BY; Rosén C; Mattsson N; Nägga K; Kilander L; Religa D; Wimo A; Winblad B; Schott JM; Blennow K; Eriksdotter M; Zetterberg H
    Brain; 2015 Sep; 138(Pt 9):2716-31. PubMed ID: 26133663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of autonomic dysfunction to CSF concentrations of noradrenaline and 3-methoxy-4-hydroxyphenylglycol in Parkinson's disease.
    Turkka JT; Juujärvi KK; Myllylä VV
    Eur Neurol; 1987; 26(1):29-34. PubMed ID: 3816883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Ritchie C; Smailagic N; Noel-Storr AH; Takwoingi Y; Flicker L; Mason SE; McShane R
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD008782. PubMed ID: 24913723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal Fluid Inflammatory Cytokine Aberrations in Alzheimer's Disease, Parkinson's Disease and Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis.
    Chen X; Hu Y; Cao Z; Liu Q; Cheng Y
    Front Immunol; 2018; 9():2122. PubMed ID: 30283455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble TREM2 is elevated in Parkinson's disease subgroups with increased CSF tau.
    Wilson EN; Swarovski MS; Linortner P; Shahid M; Zuckerman AJ; Wang Q; Channappa D; Minhas PS; Mhatre SD; Plowey ED; Quinn JF; Zabetian CP; Tian L; Longo FM; Cholerton B; Montine TJ; Poston KL; Andreasson KI
    Brain; 2020 Mar; 143(3):932-943. PubMed ID: 32065223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's disease.
    Dekker AD; Vermeiren Y; Carmona-Iragui M; Benejam B; Videla L; Gelpi E; Aerts T; Van Dam D; Fernández S; Lleó A; Videla S; Sieben A; Martin JJ; ; Blesa R; Fortea J; De Deyn PP
    Alzheimers Dement (Amst); 2018; 10():99-111. PubMed ID: 29780859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of noradrenaline in cognition and cognitive disorders.
    Holland N; Robbins TW; Rowe JB
    Brain; 2021 Sep; 144(8):2243-2256. PubMed ID: 33725122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysfunction of norepinephrine and its metabolites in Alzheimer's dementia - A review with meta-analysis.
    Portela Moreira I; Henriques T; Vieira-Coelho MA; Guimarães J
    Ageing Res Rev; 2023 Jan; 83():101784. PubMed ID: 36368648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid levels of angiotensin-converting enzyme, acetylcholinesterase, and dopamine metabolites in dementia associated with Alzheimer's disease and Parkinson's disease: a correlative study.
    Zubenko GS; Marquis JK; Volicer L; Direnfeld LK; Langlais PJ; Nixon RA
    Biol Psychiatry; 1986 Dec; 21(14):1365-81. PubMed ID: 3024746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.